Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Shimadzu Establishes Latin American Subsidiary

Published: Tuesday, November 12, 2013
Last Updated: Tuesday, November 12, 2013
Bookmark and Share
Uruguayan subsidiary will strengthen company's sales and distribution whilst providing better support for customers and distributors in Central and South America.

Shimadzu Corporation established a wholly owned subsidiary Shimadzu Latin America S.A. (SLA) in Uruguay. 

Shimadzu Corporation established Shimadzu do Brasil Comercio Ltda. (SBL, located in Sao Paulo in Brazil) in 1997 and the company has mediated sales of Shimadzu products, provided services for them in Brazil, and provided instructions and support to distributors in each country in Central and South America. As Shimadzu's business expanded in Central and South America, the percentage of SBL's businesses within Brazil increased. Also, regulations in Brazil restricted the company's trading activities with other countries in Central and South America.

Uruguay is located between Brazil and Argentina. The capital Montevideo has good access to major cities in South America. It is 30 minutes to the Argentine capital Buenos Aires by air and two hours to Sao Paulo in Brazil where SBL is located by air. Moreover, Uruguay has some advantageous features. It has free trade zones where foreign-capital organizations can establish a company easily, companies can have bonded warehouses, and the degree of financial freedom is high as compared to surrounding countries. Since Uruguay's national language is Spanish, it will be easier for SLA to strengthen sales capabilities and support systems for customers and distributors in other Spanish-speaking countries in Central and South America, as compared to SBL located in Brazil, where national language is Portuguese.

After the establishment of SLA, SLA will become the parent company of SBL and its financial settlement will be consolidated with SBL so that SLA will be the base that reflects Shimadzu's business results in Central and South America.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Shimadzu Corporation, MacCoss Lab of Biological Mass Spectrometry, UW Collaborate
The companies will leverage the power of ASCENT™ clinical solutions on ultra-fast mass spectrometry platforms.
Monday, June 16, 2014
Shimadzu and Phenomenome Discoveries Announce Exclusive Collaboration
Shimadzu and PDI will develop software tools for global profiling using high mass accuracy MSn data.
Monday, July 02, 2007
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
New Biomarker to Assess Stem Cells Developed
A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). The team's discovery offers a new way to fast-track screening methods used in stem cell research.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
Crouching Protein, Hidden Enzyme
A new study led by scientists at The Scripps Research Institute (TSRI) and the University of California (UC), Berkeley shows how a crucial molecular enzyme starts in a tucked-in somersault position and flips out when it encounters the right target.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
First 3-D Vision of Cancer Target
This basic research set the grounds for structure-based drug design approaches that could be beneficial for cancer treatments' - Dr. Cyril Dominguez, University of Leicester.
New Light Shed on Genetic Regulation
A team of scientists has uncovered greater intricacy in protein signaling than was previously understood, shedding new light on the nature of genetic production.
Hacking the Programs of Cancer Stem Cells
All tumor cells are the offspring of a single, aberrant cell, but they are not all alike.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!